Pfizer narrows post-merger R&D focus

Pfizer is whacking about 100 drug development programs out of a pipeline swollen by its merger with Wyeth.  Reuters reports that the bulk of the remaining 500 programs focus on six key areas: Oncology, pain, inflammation, Alzheimer's disease, psychoses and diabetes. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.